It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Intrinsic and extrinsic factors, including lifestyle and sun exposure, can contribute to cell senescence, which impairs skin homeostasis, that may in turn lead to skin aging. Senescent cells have a specific secretome, called the senescence-associated secretory phenotype (SASP) that includes MMPs, CXCLs and S100A8/9. Reducing the SASP with senotherapeutics is a promising strategy to reduce skin aging. Here we evaluated the effect of a formula containing niacinamide and hyaluronic acid, which are known to limit senescence and skin aging. We conducted three different studies. (1) Ex vivo explants treated with the formula had more collagen and glycosaminoglycan. (2) In a clinical trial with forty-four women, two months of treatment improved fine lines, wrinkles, luminosity, smoothness, homogeneity, and plumpness. (3) In a third study on thirty women, we treated one arm for two months and took skin biopsies to study gene expression. 101 mRNAs and 13 miRNAs were differentially expressed. We observed a likely senomorphic effect, as there was a decrease in many SASP genes including MMP12 and CXCL9 and a significant downregulation of autocrine signaling genes: S100A8 and S100A9. These pharmaco-clinical results are the first to demonstrate the senomorphic properties of an effective anti-aging formula in skin.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Bensadoun, Paul 2
; Noizet, Maïté 3
; Béganton, Benoît 3
; Philippe, Armony 3
; Alvarez-Georges, Sandrine 3
; Doat, Gautier 4
; Tourette, Amélie 3
; Bessou-Touya, Sandrine 3
; Lemaitre, Jean-Marc 2
; Duplan, Hélène 3
1 R&D Pierre Fabre Dermo-Cosmétique & Personal Care, Toulouse, France
2 Université de Montpellier, INSERM IRMB UMR1183, Hôpital Saint Eloi, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
3 R&D Pierre Fabre Dermo-Cosmétique & Personal Care, Toulouse, France (GRID:grid.121334.6)
4 Laboratoires Dermatologiques Avène, Lavaur, France (GRID:grid.121334.6)




